Product Certification&
    Enterprise Certification

  • Mr.INFO
    Tel: +86-371-55541817

  • Mobile:
  • Tel:+86-371-55541817
  • Fax:
  • URL:http://www.dakentech.com
  • Province/state:HeNan
  • City:ZhengZhou
  • Street:No.56 Hongzhuan Road,Jinshui,Zhengzhou,450000,China
  • MaxCard:
Home > Products >  Osimertinib mesylate

Osimertinib mesylate CAS NO.1421373-66-1

  • FOB Price: USD: 50.00-50.00 /Kilogram Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,Western Union
  • Available Specifications:

    AA(1-10)Kilogram

  • Product Details

Keywords

  • Osimertinib d6
  • N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate
  • AZD-9291 (Mesylate)

Quick Details

  • ProName: Osimertinib mesylate
  • CasNo: 1421373-66-1
  • Molecular Formula: C29H37N7O5S
  • Appearance: White Solid
  • Application: Used as pharmaceutical Intermeidate
  • DeliveryTime: Prompt
  • PackAge: In 25KG paper or plastic drums
  • Port: Any China port
  • ProductionCapacity: 1 Metric Ton/Day
  • Purity: 98.0%
  • Storage: Stored under room temperature in cool ...
  • Transportation: Shipped as non- dangerous chemicals
  • LimitNum: 1 Kilogram
  • Moisture Content: N/A
  • Impurity: N/A
  • N/A: N/A

Superiority

Comply with CP,JP,EP,US Grade

Osimertinib d6;N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate;AZD-9291 (Mesylate);Osimertinib methanesulfonate;Osimertinib (AZD9291) mesylate;Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);AZD-9291 mesylate N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)

Details

 
Osimertinib mesylate Basic information
Product Name: Osimertinib mesylate
Synonyms: Osimertinib d6;N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate;AZD-9291 (Mesylate);Osimertinib methanesulfonate;Osimertinib (AZD9291) mesylate;Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);AZD-9291 mesylate N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)
CAS: 1421373-66-1
MF: C29H37N7O5S
MW: 595.71298
EINECS:  
Product Categories: -;AZD09
Mol File: 1421373-66-1.mol
Osimertinib mesylate Structure
 
Osimertinib mesylate Chemical Properties
 
Safety Information
HS Code  29339900
MSDS Information
 
 
Osimertinib mesylate Usage And Synthesis
Definition ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer.
Indications The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.

 

Other products of this supplier

lookchemhot product CAS New CAS